Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma

Adoptive cell immunotherapy has been a hot spot in tumor research in recent years. Chimeric antigen receptor T cells (CAR-T) have achieved great success in hematological tumors and have changed the current tumor treatment landscape to a certain extent. However, the application of CAR-T therapy in cl...

Full description

Bibliographic Details
Published in:	Zhongliu Fangzhi Yanjiu
Main Authors:	HU Run, YAO Pei, LI Junen, GUI Renjie, DUAN Huaxin
Format:	Article
Language:	Chinese
Published:	Magazine House of Cancer Research on Prevention and Treatment 2023-12-01
Subjects:	chimeric antigen receptor natural killer cells lymphoma immunotherapy
Online Access:	http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.23.0664

Similar Items

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
by: Ali Bashiri Dezfouli, et al.
Published: (2021-12-01)

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
by: Rohtesh S. Mehta, et al.
Published: (2018-02-01)

Immunotherapy of chimeric antigen receptor NK cells: status and its promising future
by: Fang Wang, et al.
Published: (2025-10-01)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
by: Maria Giraudo, et al.
Published: (2024-03-01)

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
by: Yifan Pang, et al.
Published: (2024-04-01)

Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma
by: Tianshu Yu, et al.
Published: (2025-04-01)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
by: Ying Gong, et al.
Published: (2021-05-01)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
by: Pavel Otáhal, et al.
Published: (2016-04-01)

Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
by: Wenwen Wei, et al.
Published: (2022-11-01)

Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
by: Dongfang Liu, et al.
Published: (2017-05-01)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
by: Hamed Dabiri, et al.
Published: (2023-07-01)

CAR-NK cells in combination therapy against cancer: A potential paradigm
by: Junping Li, et al.
Published: (2024-03-01)

Modulating Cholesterol Metabolism via ACAT1 Knockdown Enhances Anti-B-Cell Lymphoma Activities of CD19-Specific Chimeric Antigen Receptor T Cells by Improving the Cell Activation and Proliferation
by: Qiong Su, et al.
Published: (2024-03-01)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
by: Jin Zhou, et al.
Published: (2022-09-01)

Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors
by: Tang-Her Jaing, et al.
Published: (2025-01-01)

A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells
by: Eunbi Yi, et al.
Published: (2025-03-01)

Cardiovascular Toxicities in Chimeric Antigen Receptor Therapy in Relapsed and Refractory Multiple Myeloma and Lymphoma Using FAERS Database
by: Fathima Shehnaz Ayoobkhan, et al.
Published: (2025-06-01)

Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor
by: Mahmoud Hassani, et al.
Published: (2020-03-01)

Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
by: Yue Huang, et al.
Published: (2022-06-01)

Targeting cancer cells: from historic methods to modern chimeric antigen receptor (CAR) T-Cell strategies
by: Kochar Khasro Saleh, et al.
Published: (2020-06-01)

Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients
by: Yuxin Zhou, et al.
Published: (2023-10-01)

The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
by: Dongfang Liu, et al.
Published: (2020-08-01)

The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
by: Elaine Tan Su Yin, et al.
Published: (2022-06-01)

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma
by: Jiaying Wu, et al.
Published: (2024-11-01)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
by: Jiaying Wu, et al.
Published: (2022-05-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
by: Yingling Zu, et al.
Published: (2024-10-01)

Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
by: Eunju Shin, et al.
Published: (2023-07-01)

Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective
by: Mehdi Bakhtiyaridovvombaygi, et al.
Published: (2024-07-01)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
by: Tahereh Soltantoyeh, et al.
Published: (2021-06-01)

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
by: Kamila Polgárová, et al.
Published: (2022-05-01)

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration
by: Katie S. Gatwood, et al.
Published: (2022-01-01)

Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression
by: Wei Jiang, et al.
Published: (2023-11-01)

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
by: Stefan Stoiber, et al.
Published: (2019-05-01)

Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion
by: Phatchanat Klaihmon, et al.
Published: (2024-07-01)

Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor
by: Mahmoud Hassani, et al.
Published: (2020-03-01)

RETRACTED: CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
by: Faroogh Marofi, et al.
Published: (2021-06-01)

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
by: Jiun-Ruey Hu, et al.
Published: (2021-08-01)

Nucleofection-based screening of chimeric antigen receptor candidates in human natural killer cells
by: Chelsia Qiuxia Wang, et al.
Published: (2025-04-01)